Jeffrey M. Holzbeierlein

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

Andrew J. Armstrong, Russell Z. Szmulewitz, Daniel P. Petrylak et al. · Journal of Clinical Oncology · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

Sam S. Chang, Bernard H. Bochner, Roger Chou et al. · The Journal of Urology · 2017 · 940 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Andrew J. Armstrong, Arun Azad, Taro Iguchi et al. · Journal of Clinical Oncology · 2022 · 299 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor Recurrence

Edward M. Messing, Catherine M. Tangen, Seth P. Lerner et al. · JAMA · 2018 · 237 citations · Full text

Medicine, Oncology, Urology +17

Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

Asim Amin, Arkadiusz Z. Dudek, Theodore F. Logan et al. · Journal for ImmunoTherapy of Cancer · 2015 · 214 citations · Full text

Medicine, Immunology, Oncology +16